Buchanan L V, Kabell G, Turcotte U M, Brunden M N, Gibson J K
Cardiovascular Diseases Research, Upjohn Company, Kalamazoo, MI 49001.
J Cardiovasc Pharmacol. 1992 Feb;19(2):256-63. doi: 10.1097/00005344-199202000-00014.
The electrophysiologic and antiarrhythmic effects of ibutilide, sotalol, and encainide were compared in dogs 24 h after myocardial infarction. Ibutilide (0.03 to 0.3 mg/kg i.v.) prevented the induction of ventricular arrhythmias in 100% of the dogs that had demonstrated inducible ventricular arrhythmias prior to treatment. This antiarrhythmic action was associated with significant increases in ventricular refractoriness and monophasic action potential duration. Sotalol (1.0 to 10.0 mg/kg i.v.) increased the ventricular refractory period and monophasic action potential duration and prevented the induction of ventricular arrhythmias in 75% of the dogs that demonstrated inducible ventricular tachyarrhythmias at baseline. Although 10 mg/kg of sotalol was required to prevent the initiation of ventricular tachycardia, this dose produced marked cardiovascular depression and hypotension in 50% of the dogs tested. Neither ibutilide nor sotalol significantly decreased the incidence of spontaneous ventricular arrhythmias. The class IC agent encainide (0.3 to 3.0 mg/kg i.v.) was successful in preventing the induction of ventricular arrhythmias in only 20% of the dogs tested. However, in contrast to ibutilide and sotalol, encainide significantly reduced spontaneous arrhythmias. Atrial and ventricular refractoriness were significantly increased only after the highest dose of encainide tested (3.0 mg/kg). Over the dose ranges studied, the relative efficacy for prevention of pacing-induced ventricular arrhythmias was ibutilide greater than sotalol much greater than encainide. For suppression of spontaneous ventricular arrhythmias, the relative efficacy was encainide much greater than ibutilide = sotalol.(ABSTRACT TRUNCATED AT 250 WORDS)
在犬心肌梗死后24小时,比较了伊布利特、索他洛尔和恩卡尼的电生理及抗心律失常作用。伊布利特(静脉注射0.03至0.3毫克/千克)可预防100%在治疗前已证明可诱发室性心律失常的犬诱发室性心律失常。这种抗心律失常作用与心室不应期和单相动作电位持续时间的显著增加有关。索他洛尔(静脉注射1.0至10.0毫克/千克)增加了心室不应期和单相动作电位持续时间,并预防了75%在基线时可诱发室性快速心律失常的犬诱发室性心律失常。虽然需要10毫克/千克的索他洛尔来预防室性心动过速的起始,但该剂量在50%受试犬中产生了明显的心血管抑制和低血压。伊布利特和索他洛尔均未显著降低自发性室性心律失常的发生率。IC类药物恩卡尼(静脉注射0.3至3.0毫克/千克)仅在20%受试犬中成功预防了室性心律失常的诱发。然而,与伊布利特和索他洛尔不同,恩卡尼显著减少了自发性心律失常。仅在测试的最高剂量恩卡尼(3.0毫克/千克)后,心房和心室不应期才显著增加。在所研究的剂量范围内,预防起搏诱发室性心律失常的相对疗效为伊布利特大于索他洛尔远大于恩卡尼。对于抑制自发性室性心律失常,相对疗效为恩卡尼远大于伊布利特=索他洛尔。(摘要截短至250字)